Publication | Closed Access
Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer
98
Citations
58
References
2008
Year
IDM-2101 was well tolerated, and evidence of efficacy was suggested.
| Year | Citations | |
|---|---|---|
Page 1
Page 1